About Us > Sabrina Witherby, MD

Sabrina Witherby, MD

Hematologist and Oncologist, Brown University Cancer Institute; Associate Professor, Warren Alpert School of Medicine at Brown University

Sabrina Witherby, MD

Highlights

  • Recognized as Rhode Island Monthly’s “Top Doctors” in 2017, 2024 and 2025
featured_paragraph

Sabrina Maria Witherby, MD is a hematologist/oncologist at the Brown University Cancer Institute with more than 24 years of clinical experience and an expertise in breast cancer. She is also an associate professor at the Warren Alpert School of Medicine at Brown University, where she is known for her commitment to patient care and medical education.

general_content

Dr. Witherby has been recognized for her contributions to the medical field, including being named one of Rhode Island Monthly’s annual “Top Doctors” in 2017, 2024, and 2025, and receiving the Beckwith Family Teaching Award from The Warren Alpert Medical School of Brown University in 2013.

She is a member of the American Society of Clinical Oncology (ASCO), the Massachusetts Medical Society, and the Association of Program Directors in Internal Medicine (APDIM) and she chairs ASCO’s Teaching and Learning Resources section of the Education Community of Practice, reflecting her dedication to advancing medical education and practice.  Dr. Witherby lives in Providence, Rhode Island with her husband and three sons.

contributions_carousel

Contributions

Alpelisib

12/02/25 | BY: Sabrina Witherby

Alpelisib (Piqray) is a targeted therapy approved to treat locally advanced or metastatic, hormone receptor-positive breast cancer that has tested positive for a mutation on the PIK3CA gene.

Read More
 | 4 Min. Read

Capivasertib

12/02/25 | BY: Sabrina Witherby

Capivasertib (Truqap) is a targeted therapy approved to treat hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancers that test positive for certain gene mutations.

Read More
 | 9 Min. Read

Inavolisib

12/02/25 | BY: Sabrina Witherby

Inavolisib (Itovebi) is a targeted therapy shown to reduce progression of certain hormone receptor-positive, HER2-negative, PIK3CA-positive metastatic breast cancers.

Read More
 | 7 Min. Read

Everolimus

12/01/25 | BY: Sabrina Witherby

Everolimus (Afinitor) is a targeted therapy that slows breast cancer growth by blocking the actions of a protein called mTOR.

Read More
 | 3 Min. Read